Physician profile
Sheetal Higbee
NPI 1154559680
$7,781.08
in general payments reported to CMS, 2019-2025
64 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $260 · 2021: $827 · 2022: $861 · 2023: $1,577 · 2024: $2,217 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,959 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,958.65 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $886.45 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $637.82 | 2019-2025 | Calquence, Tagrisso, Enhertu |
| Incyte Corporation | $532.68 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Merck Sharp & Dohme LLC | $502.16 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $458.56 | 2019-2025 | |
| Celgene Corporation | $277.33 | 2022-2025 | Reblozyl, Opdivo, Opdualag |
| Eisai INC. | $274.82 | 2019-2025 | |
| Pfizer INC. | $271.42 | 2019-2025 | |
| Daiichi Sankyo INC. | $267.46 | 2020-2025 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $259.62 | 2019-2025 | Rybrevant, Erleada |
| Astellas Pharma US INC | $234.28 | 2019-2025 | Xtandi, Padcev, Vyloy |
| Beigene USA, INC. | $210.23 | 2021-2025 | Brukinsa, Tevimbra |
| Genzyme Corporation | $177.54 | 2022-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $168.04 | 2019-2023 | Imbruvica |
| Lilly USA, LLC | $153.97 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $151.87 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Amgen INC. | $143.36 | 2019-2023 | Lumakras |
| Takeda Pharmaceuticals U.S.A., INC. | $142.83 | 2019-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Intuitive Surgical, INC. | $132.49 | 2025 | |
| Emd Serono, INC. | $111.93 | 2019-2025 | Tepmetko |
| Bayer Healthcare Pharmaceuticals INC. | $109.37 | 2019-2024 | |
| Abbvie INC. | $101.98 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $95.15 | 2024-2025 | Provenge |
| Gilead Sciences, INC. | $91.13 | 2022-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $83.98 | 2023-2025 | Libtayo |
| Seagen INC. | $81.95 | 2020-2023 | Tukysa |
| Kite Pharma, INC. | $81.47 | 2021-2024 | Yescarta |
| Taiho Oncology, INC. | $62.71 | 2024 | |
| Pharmaessentia USA Corporation | $59.17 | 2023-2025 | Besremi |
| Mirati Therapeutics, INC. | $57.81 | 2023-2024 | Krazati |
| Sobi, INC | $54.52 | 2024-2025 | |
| Adc Therapeutics America, INC. | $51.55 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $51.13 | 2023 | Precisetumor, Bracanalysis Cdx |
| Genentech USA, INC. | $49.11 | 2019-2024 | Phesgo, Tecentriq |
| Exelixis INC. | $48.93 | 2023-2024 | Cabometyx |
| Acrotech Biopharma INC. | $46.86 | 2021-2024 | Beleodaq |
| Alexion Pharmaceuticals, INC. | $46.30 | 2023-2025 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $42.91 | 2024 | Monoferric, Cosela |
| Array Biopharma INC | $42.36 | 2024 | Braftovi, Tukysa, Mektovi |
| Karyopharm Therapeutics INC. | $40.27 | 2020-2024 | Xpovio |
| Epizyme, INC. | $34.72 | 2021 | |
| Stemline Therapeutics INC. | $32.34 | 2025 | Orserdu |
| Stryker Corporation | $32.03 | 2023 | Optablate |
| Aurobindo Pharma USA, INC. | $31.67 | 2019-2020 | |
| Fennec Pharmaceuticals, INC. | $27.97 | 2024 | Pedmark |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.95 | 2024 | Gilotrif |
| Ipsen Biopharmaceuticals, INC | $23.49 | 2023 | Somatuline Depot, Onivyde |
| Deciphera Pharmaceuticals INC. | $23.29 | 2025 | Tgct, Qinlock |
| G1 Therapeutics, INC. | $20.81 | 2023 | Cosela |
| Puma Biotechnology, INC. | $17.95 | 2024 | |
| Caris Mpi, INC. | $17.78 | 2025 | Mi Cancer Seek |
| Cti Biopharma Corp. | $17.44 | 2023 | Vonjo |
| Kyowa Kirin, INC. | $17.38 | 2025 | |
| Tersera Therapeutics LLC | $17.20 | 2023 | Zoladex |
| Acceleron Pharma, INC. | $17.14 | 2021 | |
| Jazz Pharmaceuticals INC. | $16.34 | 2024 | |
| Coherus Oncology, INC. | $16.07 | 2023 | |
| Azurity Pharmaceuticals, INC. | $15.03 | 2025 | Danziten |
| Blueprint Medicines Corporation | $14.52 | 2023 | Ayvakit |
| Spectrum Pharmaceuticals INC. | $14.52 | 2024 | Rolvedon |
| Alnylam Pharmaceuticals INC. | $13.66 | 2024 | Givlaari |
| Verity Pharmaceuticals INC. | $13.61 | 2025 | Trelstar |
| Tactile Systems Technology INC | $12.94 | 2023 | Entre Plus, Flexitouch Plus |
| Foundation Medicine, INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheetal Higbee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.